Irbesartan versus placebo in combination with standard cardiovascular protection ACE-I [ACE inhibitor] therapy with ramipril for the treatment of albuminuria in hypertensive subjects at elevated cardiovascular risk.

Trial Profile

Irbesartan versus placebo in combination with standard cardiovascular protection ACE-I [ACE inhibitor] therapy with ramipril for the treatment of albuminuria in hypertensive subjects at elevated cardiovascular risk.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Irbesartan; Ramipril
  • Indications Hypertension; Proteinuria
  • Focus Therapeutic Use
  • Acronyms IMPROVE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Apr 2011 Last checked against ClinicalTrials.gov record.
    • 12 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top